Impacts of excision repair cross-complementing gene 1 (ERCC1), dihydropyrimidine dehydrogenase, and epidermal growth factor receptor on the outcomes of patients with advanced gastric cancer.
about
Prognostic value of ERCC1 mRNA expression in non-small cell lung cancer, breast cancer, and gastric cancer in patients from Southern ChinaDNA repair endonuclease ERCC1-XPF as a novel therapeutic target to overcome chemoresistance in cancer therapyPhase II trial of S-1 plus leucovorin in patients with advanced gastric cancer and clinical prediction by S-1 pharmacogenetic pathwayA retrospective analysis of second-line chemotherapy in patients with advanced gastric cancerClass III β-tubulin is a predictive marker for taxane-based chemotherapy in recurrent and metastatic gastric cancerRetrospective analyses of cisplatin-based doublet combination chemotherapy in patients with advanced gastric cancer.Proteomics identifies multipotent and low oncogenic risk stem cells of the spleen.Breast cancer resistance protein (BCRP) and excision repair cross complement-1 (ERCC1) expression in esophageal cancers and response to cisplatin and irinotecan based chemotherapy.ERCC1 polymorphisms as prognostic markers in T4 breast cancer patients treated with platinum-based chemotherapyThe prognostic impact of epidermal growth factor receptor in patients with metastatic gastric cancerAnalysis of the mRNA expression of chemotherapy-related genes in colorectal carcinoma using the danenberg tumor profile methodDifferential expression and prognostic value of ERCC1 and thymidylate synthase in resected gastric adenocarcinomaTargeted therapy in the management of advanced gastric cancer: are we making progress in the era of personalized medicine?Impact of the expression of thymidylate synthase and dihydropyrimidine dehydrogenase genes on survival in stage II/III gastric cancer.Association of thymidylate synthase expression and clinical outcomes of gastric cancer patients treated with fluoropyrimidine-based chemotherapy: a meta-analysisPolymorphisms of ERCC1 and XRCC1 predict the overall survival of advanced gastric cancer patients receiving oxaliplatin-based chemotherapy.REG Iα is a biomarker for predicting response to chemotherapy with S-1 plus cisplatin in patients with unresectable stage IV gastric cancer.ERCC1 mRNA levels and survival of advanced gastric cancer patients treated with a modified FOLFOX regimen.Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer.Biomarker analysis in stage III-IV (M0) gastric cancer patients who received curative surgery followed by adjuvant 5-fluorouracil and cisplatin chemotherapy: epidermal growth factor receptor (EGFR) associated with favourable survival.Phase II trial of docetaxel-irinotecan combination in advanced esophageal cancerERCC1 polymorphism, expression and clinical outcome of oxaliplatin-based adjuvant chemotherapy in gastric cancer.Role of the tumor microenvironment in the pathogenesis of gastric carcinoma.The Impact of the Expression Level of Intratumoral Dihydropyrimidine Dehydrogenase on Chemotherapy Sensitivity and Survival of Patients in Gastric Cancer: A Meta-Analysis.ERCC1: impact in multimodality treatment of upper gastrointestinal cancer.Anti-HER agents in gastric cancer: from bench to bedside.Novel targeted agents for gastric cancer.Molecular targeted therapies in advanced gastric cancer: does tumor histology matter?Gastric cancer pharmacogenetics: progress or old tripe?Predictive biomarker candidates for the response of gastric cancer to targeted and cytotoxic agents.How prognostic and predictive biomarkers are transforming our understanding and management of advanced gastric cancer.Clinical management of advanced gastric cancer: the role of new molecular drugs.Transcription Factor AP2ε: A Potential Predictor of Chemoresistance in Patients With Gastric Cancer.Predictive biomarkers along gastric cancer pathogenetic pathways.Integration of targeted agents in the neo-adjuvant treatment of gastro-esophageal cancers.Prognostic value of excision repair cross-complementation group 1 expression in gastric cancer: A meta-analysis.HPV Status Determines the Efficacy of Adjuvant Chemotherapy With S-1, an Oral Fluorouracil Prodrug, in Oropharyngeal Cancer.The effects of ERCC1 expression levels on the chemosensitivity of gastric cancer cells to platinum agents and survival in gastric cancer patients treated with oxaliplatin-based adjuvant chemotherapy.Prognosis of esophageal squamous cell carcinoma in patients positive for human epidermal growth factor receptor family can be improved by initial chemotherapy with docetaxel, fluorouracil, and cisplatin.Factors affecting the sensitivity of human-derived esophageal carcinoma cell lines to 5-fluorouracil and cisplatin.
P2860
Q26865990-B0BD2863-6850-45C5-A67F-C6CA8FEFC04CQ27022940-D7894EBE-B3F6-406D-A069-E87201055BD4Q30834530-7DF28616-9671-43CD-8F97-E29D08C9A254Q33428751-4980C03F-DE9F-4C09-8C7A-401CD9694065Q33589802-39D8DADB-EDA9-4261-B67F-8BDFA9F617D4Q33729150-E71B4200-264C-4221-B75B-07A74116480DQ33937536-60FEBFF6-6152-47F5-A394-3BC9CB8C07E4Q33947983-FBF3B2EB-8637-4B09-A5B0-F479BDF1ABF9Q34256001-F2FABF0B-6E43-4460-8974-9654C473C55DQ34478504-792D4D2C-9C8F-454B-903B-223249D21C2CQ34663513-A771F94C-8E9B-47D6-B8E9-EC6736380F50Q35272401-5762B3F6-AEC8-437A-B034-84A36A580C96Q35863874-15616A93-9AA4-43B6-B969-9B84CD0E57DEQ35878616-DA1E6A93-4030-4B25-907D-85FE05713CCEQ35972327-255F68B0-ECE4-476B-8A2B-E8FB8D2EDB5EQ36411838-A81EB1C5-7783-45CB-B479-1F7715792D09Q36594051-7BECBC89-66E4-4CB6-8204-996D557F4499Q36615632-FD33A070-6B40-4576-AC69-31B77E06D2CEQ37081045-8218B381-664B-4978-BC4F-268E909B31E3Q37123491-7BD5DD44-D211-4724-B5EB-40BB21FCAB9FQ37235047-2D1A8F4B-2A63-412D-A642-AC80FEBEBD98Q37397021-FE1B1602-8CDA-47F8-BE2F-A23813D84A99Q37596178-CAF451E4-AA7F-4247-B885-CCB0C2779D22Q37640119-23CE7F1C-2B78-43C6-9BFF-404D63BB7DFDQ37818224-30EC070E-E734-4D17-9A23-FE0C4A8C0943Q37885725-AF9DC220-EB70-413A-B1E6-080ED491F7C4Q38019657-2D39104D-5E76-49E9-8C75-4946EDB3C12CQ38074157-646295C3-E13D-4E26-BD92-C0D3E9C7FAD3Q38120288-79EBA1D3-29FF-4582-AE7F-5F8FDD98C2B7Q38188598-E79BC179-122B-44F7-B266-5235752E2305Q38241766-386B9D0A-74D3-4211-BA17-DB5474DBDBCCQ38263841-C12C5720-15F9-4D1A-BDCD-6CD60496F572Q38894951-9B6229D1-C98F-4260-BBF3-10955CA2C08AQ39170872-6275A93A-CCA6-4EDA-A30D-0E38D17A3F7CQ39933959-4FE7CDEC-5F2A-4978-AA18-D62B6DD36196Q41205616-4694C804-E3EE-4FB9-A0E4-31EC84A16605Q41648773-FC6B1B2E-0E2F-4153-87DB-BF983DB5972BQ41762961-5066EDE3-FD03-41EF-A01F-3C1204C25ACBQ42726594-E11E69EC-D5C0-4EB2-AE45-B95232F01BBCQ43247077-95B717CD-633E-49E1-9833-0C5D6D4C79F8
P2860
Impacts of excision repair cross-complementing gene 1 (ERCC1), dihydropyrimidine dehydrogenase, and epidermal growth factor receptor on the outcomes of patients with advanced gastric cancer.
description
2008 nî lūn-bûn
@nan
2008 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Impacts of excision repair cro ...... with advanced gastric cancer.
@ast
Impacts of excision repair cro ...... with advanced gastric cancer.
@en
Impacts of excision repair cro ...... with advanced gastric cancer.
@nl
type
label
Impacts of excision repair cro ...... with advanced gastric cancer.
@ast
Impacts of excision repair cro ...... with advanced gastric cancer.
@en
Impacts of excision repair cro ...... with advanced gastric cancer.
@nl
prefLabel
Impacts of excision repair cro ...... with advanced gastric cancer.
@ast
Impacts of excision repair cro ...... with advanced gastric cancer.
@en
Impacts of excision repair cro ...... with advanced gastric cancer.
@nl
P2093
P2860
P356
P1476
Impacts of excision repair cro ...... with advanced gastric cancer.
@en
P2093
J Matsubara
T E Nakajima
T Hamaguchi
T Kajiwara
T Moriwaki
P2860
P2888
P304
P356
10.1038/SJ.BJC.6604211
P407
P577
2008-01-29T00:00:00Z
P5875
P6179
1035664868